Listed by the USPTO as FUBARA, BLESSING M
Tech Center 3700 • Art Units: 1613 1615 1618 1693 3774
This examiner grants 62% of resolved cases
FUBARA, BLESSING M has resolved 1298 cases in Tech Center 3700 and Art Unit 1613. The allowance rate is 62.2%, and the median time to allowance is 1195 days. The 34.1% interview lift is a substantial profile feature, indicating that structured examiner discussions may play an important role in moving cases through substantive examination.
The listed companies include Novartis AG, Mayo Foundation for Medical Education and Research, and Washington University. The representative firms are Adams & Reese LH, ANDRUS INTELLECTUAL PROPERTY LAW, LLP, and Barclay Damon, LLP. The resolved-case volume supports meaningful pattern review, while the allowance rate and median timeline call for proactive case management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18977210 | Ribociclib Tablet | Final Rejection | Novartis AG |
| 18588259 | Ribociclib Tablet | Final Rejection | Novartis AG |
| 18248615 | COMPOSITIONS AND METHODS PROMOTING GROWTH OF PERIPHERAL NERVOUS TISSUE | Final Rejection | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18577357 | COMPOSITION COMPRISING A (METH)ACRYLATE COPOLYMER, AN ALKALI OR AMMONIUM SALT OF A SATURATED ALIPHATIC MONOCARBOXYLIC ACID AND SPECIFIC GLIDANTS | Non-Final OA | Evonik Operations GmbH |
| 18283344 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Non-Final OA | The Board of Regents of the University of Texas System |
| 18702531 | NANOPARTICLE-BASED ABUSE-DETERRENT FORMULATIONS AND METHODS OF MAKING AND USING | Non-Final OA | Purdue Research Foundation |
| 18994885 | COHESIVE SHEAR-THINNING BIOMATERIALS AND THE USE THEREOF | Non-Final OA | The Penn State Research Foundation |
| 17623348 | COMPOSITION COMPRISING A NATURAL DYE, A HYDRAZONO AND/OR AZO CATIONIC SYNTHETIC DIRECT DYE AND AN AROMATIC COMPOUND | Final Rejection | L'OREAL |
| 18293235 | HAIR COSMETIC COMPOSITION | Final Rejection | KAO CORPORATION |
| 18787155 | Oral Care Compositions | Non-Final OA | Colgate-Palmolive Company |
| 18825450 | Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain | Non-Final OA | Massachusetts Eye and Ear Infirmary |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy62.2% of resolved applications examined by Blessing M Fubara were allowed (1,298 resolved cases), compared with 34.0% across Art Unit 1613 over the last five years.
This examiner's interview lift is +34.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Blessing M Fubara took 1,195 days on average from filing to allowance.
Blessing M Fubara examines applications in Art Unit 1613 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
